The underlying mechanism is by MTDIA causing accumulation of MTA in tissues regardless of tumor MTAP genotype due to the loss of MTA catabolism in all cells (24, 26), thereby enhancing the MTA:SAM ratio, inhibiting PRMT5 activity, and providing dose-dependent sensitivity to MAT2a inhibitors. The gene discussed is MAT2A; the disease is neoplasm.